Overview
Cambridge-based biotech firm bit.bio has raised $50 million in funding, led by M&G Investments. The funding will accelerate product development, enhance accessibility, and expand into the toxicology market. Bit.bio's technology provides reliable human cells for research, reducing reliance on animal testing and improving pre-clinical research accuracy. CEO Przemek Obloj emphasized the importance of this investment in driving innovation in drug development.
Products
Loading...
Recent Deals
Investors: M&G Investments
Cambridge-based biotech firm bit.bio has raised $50 million in funding, led by M&G Investments. The funding will accelerate product development, enhance accessibility, and expand into the toxicology market. Bit.bio's technology provides reliable human cells for research, reducing reliance on animal testing and improving pre-clinical research accuracy. CEO Przemek Obloj emphasized the importance of this investment in driving innovation in drug development.